ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.
P/B ratio for ImmunityBio, Inc. (IBRX)
P/B ratio as of 2023: -4.35
According to ImmunityBio, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is -4.35. At the end of 2022 the company had a P/B ratio of -4.53.
P/B ratio history for ImmunityBio, Inc. from 2013 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | -4.35 |
| 2022 | -4.53 |
| 2021 | -9.77 |
| 2020 | -42.63 |
| 2019 | 12.03 |
| 2018 | 0.63 |
| 2017 | 1.65 |
| 2016 | 1.60 |
| 2015 | 3.48 |
| 2014 | 187.20 |
| 2013 | -9.54 |